World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
161
Citations
117184
World Ranking
739
National Ranking
420

Overview

Mark G. Kris is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focuses on medicine, with a strong emphasis on pulmonary and respiratory medicine, oncology, and cancer research. Additional areas of study include molecular biology and radiology, nuclear medicine, and imaging.

Their main topics of research cover several aspects of lung cancer, including treatments, mutations, diagnosis, and overall research studies. Kris also contributes to cancer genomics and diagnostics, as well as cancer immunotherapy and biomarkers. Radiomics and machine learning applications in medical imaging and studies related to colorectal cancer treatment are also among their interests.

Mark G. Kris frequently publishes in several medical and oncology journals. The most common venues for their work include:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Clinical Cancer Research
  • JCO Precision Oncology
  • Annals of Oncology

The scientist collaborates regularly with other researchers in their field. Notable co-authors include Charles M. Rudin, Jamie E. Chaft, Helena A. Yu, Gregory J. Riely, and Marc Ladanyi, reflecting active participation in collaborative research networks.

Significant recent publications by Mark G. Kris or closely related to their research interests include:

  • IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy, 2020, Journal of Thoracic Oncology
  • Antiemetics: ASCO Guideline Update, 2020, Journal of Clinical Oncology
  • Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer, 2020, Clinical Cancer Research
  • Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer, 2021, Nature Reviews Clinical Oncology
  • HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers, 2020, Cancer Discovery

Best Publications

  • EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

    William Pao;Vincent Miller;Maureen Zakowski;Jennifer Doherty

  • Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

    William Pao;Vincent A. Miller;Katerina A Politi;Gregory J. Riely

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial

    Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Thomas J. Lynch

  • Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

    Helena A. Yu;Maria E. Arcila;Natasha Rekhtman;Camelia S. Sima

  • Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

    Ethan Basch;Allison M. Deal;Mark G. Kris;Howard I. Scher

  • Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

    Frank V. Fossella;Russell DeVore;Ronald N. Kerr;Jeffrey Crawford

  • KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

    William Pao;Theresa Y Wang;Gregory J Riely;Vincent A Miller

  • Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment

    Ethan Martin Basch;Allison M. Deal;Amylou C. Dueck;Howard I. Scher

  • TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

    Roy S. Herbst;Diane Prager;Robert Hermann;Lou Fehrenbacher

  • Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

    Jeffrey Crawford;Howard Ozer;Ronald Stoller;David H Johnson

  • Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski

  • Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

    Hira Rizvi;Francisco Sanchez-Vega;Konnor La;Walid Chatila

  • Characterizing the cancer genome in lung adenocarcinoma

    Barbara A. Weir;Barbara A. Weir;Michele S. Woo;Gad Getz;Sven Perner;Sven Perner

  • Non–Small Cell Lung Cancer

    David S. Ettinger;Wallace Akerley;Gerold Bepler;Andrew Chang

  • Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.

    Kerby Shedden;Jeremy M.G. Taylor;Steven A. Enkemann;Ming Sound Tsao

  • Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

    George D. Demetri;Mark Kris;James Wade;Laurent Degos

  • ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

    Malcolm R Ranson;Lisa A Hammond;David R Ferry;Mark Kris

  • Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases

    Akihiko Yoshizawa;Noriko Motoi;Noriko Motoi;Gregory J Riely;Cami S Sima

  • Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

    Paul J. Hesketh;Mark G. Kris;Ethan Martin Basch;Kari Bohlke

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer

    Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Diane Prager

Frequent Co-Authors

Gregory J. Riely
Gregory J. Riely Memorial Sloan Kettering Cancer Center
Marc Ladanyi
Marc Ladanyi Memorial Sloan Kettering Cancer Center
Charles M. Rudin
Charles M. Rudin Memorial Sloan Kettering Cancer Center
Maria E. Arcila
Maria E. Arcila Memorial Sloan Kettering Cancer Center
William Pao
William Pao Roche (United States)
Valerie W. Rusch
Valerie W. Rusch Memorial Sloan Kettering Cancer Center
Maureen F. Zakowski
Maureen F. Zakowski Icahn School of Medicine at Mount Sinai
Naiyer A. Rizvi
Naiyer A. Rizvi Columbia University Medical Center
Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As interest grows in studying Medicine in the USA, many students are exploring related online degrees that complement traditional medical pathways. Flexible online options make it easier to balance education, work, and personal commitments while pursuing healthcare careers.

If you’re interested in mental health, psych np online programs offer a fast-track route to becoming a Psychiatric Mental Health Nurse Practitioner. This advanced nursing role is in high demand and provides essential mental health care across various settings.

For those drawn to healthcare leadership, the best online mha programs as well as the cheapest master's in healthcare administration provide pathways into management roles. These programs focus on healthcare operations, policy, and finance, opening doors to administrative positions in hospitals and clinics.

Those seeking the highest levels of clinical expertise may consider the most affordable online dnp programs. Earning a Doctor of Nursing Practice (DNP) prepares graduates for leadership roles, advanced practice, and evidence-based patient care.

Online healthcare degrees not only offer convenience, but can also help reduce educational costs, making advanced medical careers more accessible than ever.

Best Scientists Citing Mark G. Kris

Trending Scientists

Recently Published Articles